Synopsis India’s core industries are transforming as the nation advances toward Viksit Bharat. In 2026, technology-led reinvention, sustainability, and talent transformation are key drivers. AI, smart systems, and digitalization are reshaping manufacturing, energy, healthcare, and finance, while companies focus on low-carbon operations and workforce upskilling. AgenciesThis is a representative image.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Arnab Basu
Future Directions in nccRCC
The treatment of nccRCC remains a significant challenge due to its rarity and biological heterogeneity. As a result, clinical trials for nccRCC often lag behind those for clear cell subtypes, with limited resources and smaller patient populations slowing progress. However, several randomized trials currently in development, such as PAPMET2 and studies under the STELLAR program, aim to better define the role of immunotherapy and targeted therapy combinations in subtypes like papillary RCC.
Future Directions in ccRCC
The future of ccRCC treatment centers around optimizing the use of current therapies through smarter sequencing and combination strategies while also developing novel agents with new mechanisms of action. Several cooperative group trials are investigating how best to incorporate available drugs, as many current treatments lead to early tumor shrinkage followed by prolonged stable disease.
Durability of Response and Histology-Specific Insights
Durability of Response and Histology-Specific Insights The most surprising finding from the KEYNOTE-B61 study was the substantial activity observed in chromophobe RCC, a histologic subtype that has historically been considered poorly responsive to immunotherapy due to its low tumor mutational burden. Previous retrospective studies and the prospective nivolumab plus cabozantinib study from Memorial Sloan Kettering had demonstrated limited immunotherapy responsiveness in chromophobe tumors.
Efficacy Findings: Response and Disease Control Rates
Efficacy Findings: Response and Disease Control Rates The KEYNOTE-B61 study demonstrated remarkable efficacy results with an objective response rate of 50.6% across all histologies, representing a substantial improvement over historical outcomes in non–clear cell RCC. The disease control rate reached 82%, meaning the overwhelming majority of patients achieved at least stable disease or better.
Role of Biomarkers
The evolving treatment landscape in RCC continues to highlight a critical challenge: the lack of reliable biomarkers to guide therapy selection. Although clinical factors such as International mRCC Database Consortium risk help categorize patients, they don’t fully predict who will respond best to certain treatments like immunotherapy or VEGF inhibitors.
Was Mosunetuzumab/Polatuzumab Vedotin Efficacious in LBCL Subtype?
In patients with autologous stem cell transplant-ineligible relapsed/refractory large B-cell lymphoma, mosunetuzumab-axgb (Lunsumio) in combination with polatuzumab vedotin-piiq (Polivy; M-Pola) achieved a 59% reduction in the risk of progression or death compared with rituximab (Rituxan) plus gemcitabine and oxaliplatin (R-GemOx; HR, 0.41; 95% CI, 0.28-0.61; P <.0001).
Five-Year Cancer Survival Rates Lower Among Rural Cancer Populations
An American Cancer Society (ACS)–based study published in Cancer showed that 5-year cancer survival rates were lower among non-metropolitan patients who were Black and White in the US vs their metropolitan counterparts.1 Specifically, in localized-stage, regional-stage, and distant-stage cancers, the overall survival (OS) rates among Black and White patients were 2%, 5%, and 3% to 7% lower in nonmetropolitan vs metropolitan areas, respectively.
Atembimetinib Plus SOC Chemo Improves Survival/Safety in 1L PDAC
Atebimetinib (IMM-1-104) combined with modified gemcitabine and nab-paclitaxel (Abraxane) demonstrated positive survival and safety data as a frontline therapy for patients with pancreatic cancer, according to a press release from the developer, Immuneering.1 The results came from an open-label, dose-exploration and expansion phase 1/2a trial (NCT05585320), which evaluated atebimetinib alone and with other approved agents in patients with RAS-mutated or RAS/MPK activated advanced or...
Oral Agents Provide Greater Acute Myeloid Leukemia Treatment Diversity
Treatment for those with acute myeloid leukemia (AML) depends on a variety of factors, according to Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, which include stage of treatment, transplant eligibility, and mutational status. In an interview with CancerNetwork®, Mahmoudjafari discussed standard pharmacologic options for patients being treated for AML. She began by highlighting the emergence of oral options for these patients, who historically were limited to intravenous (IV) induction therapy.
Diving Into the Practical Applications of ctDNA in Oncology Care
In this episode of Oncology Decoded, hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discussed the role that circulating tumor DNA (ctDNA) may play in the monitoring and management of genitourinary cancers as well as other disease types with their colleague, Arnab Basu, MBBS, MPH, FACP.
Adverse Event Management Strategies in Renal Cell Carcinoma
September 19, 2025 By Panelists discuss the nuanced approach to adverse effect management in non–clear cell renal cell carcinoma (nccRCC), highlighting a shift from aggressive toxicity management in the first-line setting aimed at prolonging survival to a patient-centered focus on quality of life and tolerability in later lines, emphasizing open communication and long-term treatment endurance.
Clinical Experience in Treating nccRCC (Patient Case 2)
September 19, 2025 By Panelists discuss the complex management of papillary renal cell carcinoma (RCC) after first-line progression, focusing on balancing effective second-line therapies like lenvatinib plus pembrolizumab with quality of life, the role of multidisciplinary care and surgery, the importance of close monitoring, and the critical need for clinical trial enrollment and genomic profiling to guide personalized treatment.
Overview of the Second-Line nccRCC Treatment Landscape
September 12, 2025 By Panelists discuss the challenges of treating non–clear cell renal cell carcinoma (nccRCC) after first-line progression, emphasizing the limited second-line options, the emerging use of immunotherapy (IO) and combination regimens, the need for subtype-specific strategies, and the critical role of clinical trial enrollment to advance care in this heterogeneous disease. Treating nccRCC after progression on first-line therapy remains a significant challenge.
Overview of the First-Line nccRCC Treatment Landscape
September 12, 2025 By Panelists discuss recent advances in non–clear cell renal cell carcinoma (nccRCC) treatment, highlighting the emerging role of immunotherapy plus tyrosine kinase inhibitor (TKI) combinations—particularly lenvatinib and pembrolizumab—in improving response rates, progression-free survival, and overall survival across diverse subtypes, while emphasizing individualized care and proactive management.
Clinical Experience in Treating ccRCC (Patient Case 1)
September 5, 2025 By Panelists discuss the challenges of managing intermediate-risk metastatic clear cell renal cell carcinoma (ccRCC) after progression on first-line immunotherapy (IO)/tyrosine kinase inhibitor (TKI) therapy, emphasizing cabozantinib’s role, individualized dosing strategies, proactive toxicity management, and the importance of patient-centered care to optimize long-term disease control and quality of life.
Overview of the Second-Line ccRCC Treatment Landscape
September 5, 2025 By Panelists discuss evolving second-line treatment strategies for clear cell renal cell carcinoma (ccRCC), emphasizing the impact of first-line regimens, the growing role of tyrosine kinase inhibitors (TKIs) and emerging combinations, and the need for clinical judgment in sequencing therapies to balance disease control, symptom management, and patient quality of life.
Treatment Management Strategies
August 29, 2025 By Panelists discuss the shift toward a more personalized approach in metastatic renal cell carcinoma (RCC) management, highlighting the evolving role of risk stratification, the renewed interest in immune checkpoint inhibitors for favorable-risk patients, and the strategic integration of systemic therapy, active surveillance, and surgical interventions to optimize long-term outcomes.
Overview of the First-Line ccRCC Treatment Landscape
August 29, 2025 By Panelists discuss current strategies for first-line treatment sequencing in renal cell carcinoma (RCC), emphasizing immunotherapy-based combinations tailored to disease burden and patient characteristics, while highlighting the importance of multidisciplinary care, real-world experience, and clinical trial data in guiding personalized, patient-centered decisions.
Future of Data Storage Archives
The future of data storage is rapidly evolving, driven by advancements in technology and increasing data demands. Explore blogs that uncover the latest trends, technologies, and breakthroughs from Pure Storage enabling a data-driven future defined by AI, HPC, and more.
From Now to Next: The Full Lifecycle Experience of FlashArray//RC20
With enterprise-grade architecture, AI-powered support, and lifecycle planning that adapts to your pace, FlashArray//RC20 delivers the performance, optionality, and clarity you need today—with room to grow tomorrow. Meet Alex. Alex runs IT for a fast-growing manufacturer. Some days, she’s focused on keeping ERP, file services, and backups stable with a lean team and a leaner budget.
Inside FlashArray//RC20: Engineered Reuse, Trusted Architecture, Transparent Lifecycle
FlashArray//RC20 is the newest enterprise-grade storage solution designed with sustainability, reliability, and accessibility in mind. FlashArray//RC20 brings the trusted architecture and support model to a broader audience by using engineered reuse and full-lifecycle support to make enterprise-grade storage more accessible than ever.
From Evergreen to FlashArray//RC20: Innovation Flies Again
FlashArray//RC20 is a capacity-optimized entry-level enterprise storage array built using renewed and brand-new components. Made possible by Evergreen, FlashArray//RC20 showcases our engineering discipline, customer-first design, and strategic reuse model. Picture this: A rocket that lands itself, gets refueled, and launches again—reliably, and more affordably than ever before. SpaceX made that real, and in doing so, redefined aerospace economics.
Current update on pharmacological strategies of penile cancer
As a service to authors and researchers we are providing this version of an accepted manuscript (AM). Copyediting, typesetting, and review of the resulting proofs will be undertaken on this manuscript before final publication of the Version of Record (VoR). During production and pre-press, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal relate to these versions also.
Social Connections and COVID19 Vaccination
Conflicts of Interest The authors declare no conflicts of interest. References , and . 2021. “Implementation of State Vaccine Incentive Lottery Programs and Uptake of Covid-19 Vaccinations in the United States.” JAMA Network Open 4, no. 12: e2138238. https://doi.org/10.1001/jamanetworkopen.2021.38238. , , and . 2023. “More Than Words: Leaders’ Speech and Risky Behavior During a Pandemic.” American Economic Journal: Economic Policy 15, no. 3: 351–371. https://doi.org/10.1001/10.1257/pol.20210284.
Higher education, industrial strategy, and the importance of place
As co-founder of a Durham University spinout, operating in the northeast of England for 20 years, I know first-hand how university R&D can be translated into products and services that drive growth and create skilled jobs. My company, Kromek Group, originated in Durham University research into cutting-edge radiation detection technology, and now delivers breakthroughs applied everywhere from local hospitals to the frontline in Ukraine, employing more than 150 people across two continents.
Arnab Basu
firstname surname Email Organisation Job Title* Job Area Job Level By submitting you agree to our terms and conditions
Budget presents an opportunity to drive Viksit Bharat's manufacturing-led expansion
: FY25 has begun on a good note for Indian manufacturing. According to the Reserve Bank of India, capacity utilisation in manufacturing rose to 76.5% in Q4 of 2023-24 from 74.7% in the preceding quarter, reaching well above the long-term average of 73.8%. Moreover, the contribution of high-end manufacturing exports to GDP improved during FY24. For example, India’s electronics exports increased 23.6% to US$29.12 billion in FY24.
Governance Matters : The Persistence of Rural-governed Urban Settlements in India
The Persistence of Rural-governed Urban Settlements in India A dual-track system of local governance provides the state governments in India the authority to designate a rural-governed or an urban-governed status for each settlement. Spatially, though, the term “urban” has no universal cut-off. Thus, an urban settlement as defined by the Indian census may well be designated as rural-governed.
Kromek Group PLC Placing, Subscription, Open Offer and Notice of GM
Kromek (LSE:KMK) Intraday Stock Chart Friday 5 May 2023 TIDMKMK RNS Number : 6336Y Kromek Group PLC 05 May 2023 The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under The Market Abuse Regulation (EU 596/2014) pursuant to the Market Abuse (Amendment) (EU Exit) Regulations 2018.
How To Unlock Super Saiyan 4 Goku In Xenoverse 2? Answered
Everybody has heard of the anime Dragon Ball Z, and that has been made into a game, but it is like the adaptation in Roblox that was made for Naruto called Shindo Life. The developer of Xenoverse 2 is Dimps, and this is a continuation of its predecessor, so this can be called more of a sequel. This would be the fourth game that lets you customize your character and lets you choose your character from one of the five races that are Saiyan, Humans, Maijins, Namekians, and Frieza.
Budget 2021: Time to rethink, reconfigure, reinvent
As a fiscal roadmap to reinstate and revive India’s economic recovery, the spending oriented Union Budget 2021 comes across as an exercise in prudence. Underscoring the theme of ‘rethink, reconfigure and reinvent’ to address some of the immediate, mid term and long standing issues that needed weeding out, this Budget seems to have something for everyone, albeit in a conservative manner.
Why Angelo Mathews Is A Sri Lankan Legend
WELLINGTON, NEW ZEALAND - DECEMBER 18: Angelo Mathews of Sri Lanka celebrates his century with Kusal Mendis during day four of the First Test match in the series between New Zealand and Sri Lanka at Basin Reserve on December 18, 2018 in Wellington, New Zealand. (Photo by Hagen Hopkins/Getty Images) Describe Angelo Mathews in just one word? Superstar! In this article, we will explore the career of Angelo Mathews.
Last Word on Cricket
SYDNEY, AUSTRALIA - JANUARY 05: Younis Khan of Pakistan celebrates his century during day three of the Third Test match between Australia and Pakistan at Sydney Cricket Ground on January 5, 2017 in Sydney, Australia. (Photo by Mark Kolbe/Getty Images) Younis Khan. The legend. The captain. On this day 11 years ago, Pakistan became the second team to win the T20 world cup.
The hibernating 100S complex is a target of ribosome-recycling factor and elongation factor G in Staphylococcus aureus
Arnab Basu‡, Kathryn E. Shields‡ and Mee-Ngan F. Yap‡,§1 ‡Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, Saint Louis, Missouri 63104 §Department of Microbiology-Immunology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611 ↵1 To whom correspondence should be addressed: Dept. of Microbiology-Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611.
The hibernating 100S complex is a target of ribosome-recycling factor and elongation factor G in Staphylococcus aureus
Arnab Basu1, Kathryn E Shields1 and Mee-Ngan F Yap2* 1Saint Louis University, United States 2Microbiology-Immunology, Northwestern University, United States ↵* Corresponding author; email: frances.yap{at}northwestern.edu Author contributions: A.B. data curation; A.B. and M.-N.F.Y. formal analysis; A.B. validation; A.B., K.E.S., and M.-N.F.Y. investigation; A.B. visualization; A.B., K.E.S., and M.-N.F.Y. methodology; A.B. and M.-N.F.Y. writing-original draft; M.-N.F.Y. conceptualization;...
Nivolumab-induced hypophysitis leading to hypopituitarism and secondary empty sella syndrome in a patient with non-small cell lung cancer
Unexpected outcome (positive or negative) including adverse drug reactions Nivolumab-induced hypophysitis leading to hypopituitarism and secondary empty sella syndrome in a patient with non-small cell lung cancer Jeremy Chang1, Jeffrey Tran1, Dina Kamel1 and Arnab Basu2 1 Internal Medicine, University of Southern California, Los Angeles, California, USA 2 Hematology/Oncology, University of Southern California—Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, USA...
Immune Response Markers in Matched RCC Tissue Specimens
Abstract and Introduction Abstract Objectives: Immune checkpoint therapy has been promising in renal cell carcinoma, but no validated clinically relevant biomarkers exist. Metastatic deposits may have discordant biomarker expression. Methods: Fifty matched pairs of primary and metastatic kidney tumors were evaluated via immunohistochemistry for immune checkpoint proteins PD-1, PD-L1, and PD-L2 and the T-cell and macrophage surface markers CD3, FOXP3, and CD163.
Thermal and Nutritional Regulation of Ribosome Hibernation in Staphylococcus aureus
ABSTRACT The translationally silent 100S ribosome is a poorly understood form of the dimeric 70S complex that is ubiquitously found in all bacterial phyla. The elimination of the hibernating 100S ribosome leads to translational derepression, ribosome instability, antibiotic sensitivity, and biofilm defects in some bacteria.
Thermal and nutritional regulation of ribosome hibernation in Staphylococcus aureus
ABSTRACTThe translationally silent 100S ribosome is a poorly understood form of the dimeric 70S complex that is ubiquitously found in all bacterial phyla. Eliminating the hibernating 100S ribosome leads to translational derepression, ribosome instability, antibiotic sensitivity, and biofilm defects in some bacteria.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Arnab
Contact Arnab, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack